Publication: Valacyclovir for herpes simplex encephalitis
Issued Date
2011-07-01
Resource Type
ISSN
10986596
00664804
00664804
Other identifier(s)
2-s2.0-79959249152
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antimicrobial Agents and Chemotherapy. Vol.55, No.7 (2011), 3624-3626
Suggested Citation
Thomas Pouplin, Julie Nguyen Pouplin, Pham Van Toi, Niklas Lindegardh, H. Rogier Van Doorn, Tran Tinh Hien, Jeremy Farrar, M. Estée Török, Tran Thi Hong Chau Valacyclovir for herpes simplex encephalitis. Antimicrobial Agents and Chemotherapy. Vol.55, No.7 (2011), 3624-3626. doi:10.1128/AAC.01023-10 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12451
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Valacyclovir for herpes simplex encephalitis
Other Contributor(s)
Abstract
The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings. Copyright © 2011, American Society for Microbiology. All Rights Reserved.